CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. More Details
Flawless balance sheet with reasonable growth potential.
Share Price & News
How has CareDx's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CDNA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: CDNA's weekly volatility (11%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: CDNA exceeded the US Biotechs industry which returned 22.3% over the past year.
Return vs Market: CDNA exceeded the US Market which returned 53.8% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is CareDx's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StEstimating The Fair Value Of CareDx, Inc (NASDAQ:CDNA)
1 month ago | Simply Wall StLoss-Making CareDx, Inc (NASDAQ:CDNA) Expected To Breakeven In The Medium-Term
2 months ago | Simply Wall StDid CareDx, Inc (NASDAQ:CDNA) Insiders Sell Shares?
Is CareDx undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: CDNA ($74.27) is trading above our estimate of fair value ($65.32)
Significantly Below Fair Value: CDNA is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: CDNA is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: CDNA is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CDNA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CDNA is overvalued based on its PB Ratio (13.2x) compared to the US Biotechs industry average (3.7x).
How is CareDx forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CDNA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: CDNA is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: CDNA's is expected to become profitable in the next 3 years.
Revenue vs Market: CDNA's revenue (18.7% per year) is forecast to grow faster than the US market (9.3% per year).
High Growth Revenue: CDNA's revenue (18.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CDNA's Return on Equity is forecast to be high in 3 years time
How has CareDx performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CDNA is currently unprofitable.
Growing Profit Margin: CDNA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CDNA is unprofitable, but has reduced losses over the past 5 years at a rate of 3.2% per year.
Accelerating Growth: Unable to compare CDNA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CDNA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.3%).
Return on Equity
High ROE: CDNA has a negative Return on Equity (-6.74%), as it is currently unprofitable.
How is CareDx's financial position?
Financial Position Analysis
Short Term Liabilities: CDNA's short term assets ($273.1M) exceed its short term liabilities ($69.2M).
Long Term Liabilities: CDNA's short term assets ($273.1M) exceed its long term liabilities ($21.6M).
Debt to Equity History and Analysis
Debt Level: CDNA is debt free.
Reducing Debt: CDNA has no debt compared to 5 years ago when its debt to equity ratio was 53.8%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable CDNA has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: CDNA is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 27.3% per year.
What is CareDx current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CDNA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CDNA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CDNA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CDNA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CDNA's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Reg Seeto (48 yo)
Dr. Reginald Seeto, also known as Reg, M.D., MBBS, has been the President at CareDx, Inc. since November 26, 2018 and its Chief Executive Officer and Director since November 1, 2020. He served as Chief Bus...
CEO Compensation Analysis
Compensation vs Market: Reg's total compensation ($USD1.96M) is below average for companies of similar size in the US market ($USD5.16M).
Compensation vs Earnings: Reg's compensation has been consistent with company performance over the past year.
Experienced Management: CDNA's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.
Experienced Board: CDNA's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20.9%.
CareDx, Inc's company bio, employee growth, exchange listings and data sources
- Name: CareDx, Inc
- Ticker: CDNA
- Exchange: NasdaqGM
- Founded: 1998
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$3.849b
- Shares outstanding: 51.82m
- Website: https://www.caredx.com
Number of Employees
- CareDx, Inc
- 1 Tower Place
- 9th Floor
- South San Francisco
- United States
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It offers AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/04/19 22:12|
|End of Day Share Price||2021/04/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.